v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Information  
Schedule of significant expense categories

The table below summarizes the significant expense categories regularly provided to the CODM for the six months ended June 30, 2025 and 2024:

Six Months Ended June 30,

(in thousands)

    

2025

    

2024

Operating expenses:

Research and development: Firmonertinib (excluding personnel-related and other internal costs):

FURTHER

$

5,443

$

7,334

FURVENT

19,235

15,300

FAVOUR

73

30

Other Firmonertinib costs

6,035

1,569

Total Firmonertinib

30,786

24,233

Research and development: Discovery-stage programs

44,606

6,614

Research and development: Personnel-related and other internal costs

13,617

7,906

General and administrative: Personnel-related costs

6,792

4,004

General and administrative: Other costs

4,594

3,614

Other segment items (a)

(4,609)

(7,080)

Net loss

$

(95,786)

$

(39,291)

(a) Other segment items consists of interest and investment income.